Biohaven Ltd. (BHVN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $9.02: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality; Negative price momentum.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and... Read more
Sell if holding. Engine safety override at $9.02: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 82d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Biohaven Ltd.
Latest news
- Morgan Stanley Maintains Overweight on Biohaven, Lowers Price Target to $18 — benzinga May 13, 2026 neutral
- RBC Capital Maintains Outperform on Biohaven, Lowers Price Target to $22 — benzinga May 5, 2026 positive
- Biohaven Files Prospectus For Offering Mixed Shelf; Terms Undisclosed — benzinga May 4, 2026 neutral
- Biohaven Q1 Adj. EPS $(0.69) Beats $(0.78) Estimate — benzinga May 4, 2026 positive
Generated 2026-05-20T22:01:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 7.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.02: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $8.23. Score 4.8/10, moderate confidence.
Take-profit target: $19.59 (+121.4% upside). Prior stop was $8.23. Stop-loss: $8.23.
Quality below floor (1.4 < 4.0).
Biohaven Ltd. trades at a P/E of N/A (forward -4.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
25 analysts cover BHVN with a consensus score of 4.0/5. Average price target: $22.
What does Biohaven Ltd. do?Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments...
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.